SARS-CoV-2 IgG Levels Allow Predicting the Optimal Time Span of Convalescent Plasma Donor Suitability.
COVID-19
SARS-CoV-2 antibodies
convalescent plasma
plasmapheresis
Journal
Diagnostics (Basel, Switzerland)
ISSN: 2075-4418
Titre abrégé: Diagnostics (Basel)
Pays: Switzerland
ID NLM: 101658402
Informations de publication
Date de publication:
22 Oct 2022
22 Oct 2022
Historique:
received:
27
09
2022
revised:
14
10
2022
accepted:
21
10
2022
entrez:
11
11
2022
pubmed:
12
11
2022
medline:
12
11
2022
Statut:
epublish
Résumé
Convalescent plasma (CP) has been in use for the treatment of numerous infectious diseases for more than a century, recently also for coronavirus disease 2019 (COVID-19). A major challenge for this treatment is identifying suitable donors with sufficient levels of functional antibodies and to determine the optimal time span for CP donation. In this retrospective study, we analyzed 189 CP donations of 66 donors regarding anti-SARS-CoV-2 anti-S IgG antibody levels. We found a significant correlation between the semi-quantitative SARS-CoV-2 IgG ratio values and in vitro antibody functionality. A time-to-event analysis allowed us to predict the optimal time span of COVID-19 CP donor suitability. We found that high IgG ratio values, which significantly correlate with high in vitro antibody functionality, were suitable for CP donation for a median of 134 days after the first CP donation. Donors with lower IgG ratios were suitable for a median of 53 days. Our data support plasma collection centers to determine optimal points in time for CP donation by means of widely used semi-quantitative laboratory IgG ratio values.
Identifiants
pubmed: 36359411
pii: diagnostics12112567
doi: 10.3390/diagnostics12112567
pmc: PMC9689947
pii:
doi:
Types de publication
Journal Article
Langues
eng
Subventions
Organisme : WISS 2025 project 'IDA-Lab Salzburg'
ID : 20204-WISS/225/197-2019 and 20102-F1901166-KZP
Références
Vox Sang. 2020 Aug;115(6):507-514
pubmed: 32516839
Clin Microbiol Rev. 2022 Sep 21;35(3):e0020021
pubmed: 35262370
Cureus. 2022 Jun 23;14(6):e26239
pubmed: 35898366
N Engl J Med. 2021 Apr 15;384(15):1412-1423
pubmed: 33626250
Science. 2022 Jul 8;377(6602):138-139
pubmed: 35857562
Infection. 2021 Dec;49(6):1187-1194
pubmed: 34132990
Intensive Care Med. 2021 May;47(5):521-537
pubmed: 33876268
Ann Med. 2022 Dec;54(1):516-523
pubmed: 35118917
N Engl J Med. 2021 Feb 4;384(5):403-416
pubmed: 33378609
Transfusion. 2022 Mar;62(3):556-562
pubmed: 35041206
J Int Med Res. 2022 Jan;50(1):3000605211069279
pubmed: 34986676
Int J Infect Dis. 2020 Dec;101:314-322
pubmed: 33045429
Eur Respir J. 2022 Feb 10;59(2):
pubmed: 34531275
JAMA Netw Open. 2021 Mar 1;4(3):e214302
pubmed: 33749770
Front Med (Lausanne). 2021 Jun 07;8:684151
pubmed: 34164419
Nat Med. 2020 Aug;26(8):1200-1204
pubmed: 32555424
Front Immunol. 2021 Jun 16;12:708523
pubmed: 34220870
JAMA. 2020 Apr 28;323(16):1582-1589
pubmed: 32219428
N Engl J Med. 2021 Mar 18;384(11):1015-1027
pubmed: 33523609
Infect Dis (Lond). 2021 Nov;53(11):820-829
pubmed: 34128763
Sci Immunol. 2020 Dec 7;5(54):
pubmed: 33288645
Emergencias. 2021 Abr;33(2):137-138
pubmed: 33750056
J Infect Dis. 2020 Jun 16;222(1):38-43
pubmed: 32348485
Transfusion. 2020 Aug;60(8):1773-1777
pubmed: 32491199
Science. 2021 Dec 24;374(6575):1586-1593
pubmed: 34726479
Clin Infect Dis. 2022 Jun 02;:
pubmed: 35653428
N Engl J Med. 2021 Sep 16;385(12):1078-1090
pubmed: 34432976
PLoS One. 2021 Nov 2;16(11):e0250541
pubmed: 34727115
Signal Transduct Target Ther. 2020 Sep 2;5(1):180
pubmed: 32879307
JAMA Oncol. 2021 Jun 17;:
pubmed: 34137799
J Med Virol. 2020 Oct;92(10):1890-1901
pubmed: 32293713
Front Immunol. 2022 Feb 07;13:817829
pubmed: 35197981
J Clin Invest. 2020 Nov 2;130(11):6141-6150
pubmed: 32764200
Viruses. 2022 Mar 18;14(3):
pubmed: 35337044
Sensors (Basel). 2021 Oct 01;21(19):
pubmed: 34640901
Mayo Clin Proc. 2021 May;96(5):1262-1275
pubmed: 33958057
N Engl J Med. 2021 Feb 18;384(7):619-629
pubmed: 33232588
Talanta. 2022 Jul 1;244:123409
pubmed: 35390680
N Engl J Med. 2021 Feb 18;384(7):610-618
pubmed: 33406353